Findings From Open-Label Extension Study and Qualitative Patient Interview Study of GIVLAARI® (givosiran) Presented at European Association for the Study of the Liver (EASL) Congress 2023

07 Jul, 2023 Findings From Open-Label Extension Study and Qualitative Patient Interview Study of GIVLAARI® (givosiran) Presented at European Association for the Study of the Liver (EASL) Congress 2023

At the European Association for the Study of the Liver (EASL) Congress 2023, we presented results from a Phase 1/2, 48-month, open-label extension study and a qualitative patient interview study of givosiran.

Sardh, et al. “Final Results from a Phase 1/2, 48-Month, Open-Label Extension Study of Givosiran in Patients with Acute Intermittent Porphyria
Lombardelli, et al. “Patient Experience with Acute Hepatic Porphyria before and after long-term givosiran treatment: a qualitative interview study”